OverviewSuggest Edit

Editas Medicine is a transformative genome editing company that is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The Company operates through developing and commercializing genome editing technology segment. Editas Medicine is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats technology.
TypePublic
Founded2013
HQCambridge, US
Websiteeditasmedicine.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Sep 2019)179(+35%)
Job Openings29
Revenue (FY, 2018)$31.9 M(+133%)
Share Price (Nov 2019)$23.2 (+2%)

Key People/Management at Editas Medicine

Katrine Bosley

Katrine Bosley

CEO
Andrew Hack

Andrew Hack

CFO
Gerald Cox

Gerald Cox

Chief Medical Officer
Charles Albright

Charles Albright

Chief Scientific Officer
Keith Joung

Keith Joung

Co - Founder
Show more

Editas Medicine Office Locations

Editas Medicine has offices in Cambridge and Boulder
Cambridge, US (HQ)
11 Hurley St
Boulder, US
4909 Nautilus Ct N Suite 208/211
Cambridge, US
300 Third St
Show all (3)

Editas Medicine Financials and Metrics

Editas Medicine Revenue

Editas Medicine's revenue was reported to be $31.94 m in FY, 2018
USD

Net income (Q3, 2019)

(32.9m)

EBIT (Q3, 2019)

(34.6m)

Market capitalization (18-Nov-2019)

1.2b

Closing stock price (18-Nov-2019)

23.2

Cash (30-Sep-2019)

104.8m
Editas Medicine's current market capitalization is $1.2 b.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

6.1m13.7m31.9m

General and administrative expense

46.3m50.5m55.0m

R&D expense

57.0m83.2m90.7m

Operating expense total

103.2m133.7m145.7m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

805.0k3.4m962.0k682.0k3.1m6.3m3.9m7.4m14.5m2.1m2.3m

General and administrative expense

9.8m12.2m11.3m12.3m11.9m12.6m14.2m14.3m13.3m17.5m14.4m15.7m

R&D expense

8.9m10.4m10.8m19.0m17.3m20.4m21.3m32.7m17.4m15.8m23.6m22.7m

Operating expense total

18.6m22.6m22.1m31.3m29.2m33.0m35.5m47.0m30.8m33.3m38.0m38.4m
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

185.3m146.6m134.8m

Accounts Receivable

88.0k679.0k30.0k

Prepaid Expenses

2.4m5.8m

Inventories

1.8m
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(97.2m)(120.3m)(110.0m)

Depreciation and Amortization

2.7m3.3m

Inventories

1.8m

Accounts Payable

4.6m(1.5m)1.8m
Quarterly
USDY, 2019

Financial Leverage

1.8 x
Show all financial metrics

Editas Medicine Operating Metrics

FY, 2016

Patents Issued

41

Patents Pending

500
Show all operating metrics

Editas Medicine Online and Social Media Presence

Embed Graph

Editas Medicine News and Updates

Editas Medicine Announces Third Quarter 2019 Results and Update

Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine

Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases

CAMBRIDGE, Mass. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Asklepios BioPharmaceutical, Inc. (AskBio), a fully integrated adeno-associated virus (AAV) gene therapy company, today announced the com…

Editas Medicine Announces Second Quarter 2019 Results and Update

Cynthia (Cindy) Collins named President and Chief Executive Officer

Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association

IND-enabling activities initiated for EDIT-301, a potentially best-in-class experimental medicine for the treatment of sickle cell disease and beta-thalassemia

Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia

Data support opportunities to develop best-in-class, durable medicines for hemoglobinopathies Data support opportunities to develop best-in-class, durable medicines for hemoglobinopathies

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference

CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the U.S. Patent and Trademark Office (USPTO) decision that ended the U.S. patent inter…
Show more

Editas Medicine Frequently Asked Questions

  • When was Editas Medicine founded?

    Editas Medicine was founded in 2013.

  • Who are Editas Medicine key executives?

    Editas Medicine's key executives are Katrine Bosley, Andrew Hack and Gerald Cox.

  • How many employees does Editas Medicine have?

    Editas Medicine has 179 employees.

  • What is Editas Medicine revenue?

    Latest Editas Medicine annual revenue is $31.9 m.

  • What is Editas Medicine revenue per employee?

    Latest Editas Medicine revenue per employee is $178.4 k.

  • Who are Editas Medicine competitors?

    Competitors of Editas Medicine include Biocytogen, Evolutionary Genomics and Asimov.

  • Where is Editas Medicine headquarters?

    Editas Medicine headquarters is located at 11 Hurley St, Cambridge.

  • Where are Editas Medicine offices?

    Editas Medicine has offices in Cambridge and Boulder.

  • How many offices does Editas Medicine have?

    Editas Medicine has 3 offices.